Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
15,158
ISIN
US75886F1075
Website
Regeneron Metrics
BasicAdvanced
$54B
13.03
$39.43
0.43
$1.76
0.69%
Price and volume
Market cap
$54B
Beta
0.43
52-week high
$1,206.81
52-week low
$476.49
Average daily volume
1.5M
Dividend rate
$1.76
Financial strength
Current ratio
5.708
Quick ratio
3.9
Long term debt to equity
9.204
Total debt to equity
9.204
Dividend payout ratio (TTM)
2.08%
Interest coverage (TTM)
83.17%
Profitability
EBITDA (TTM)
4,448
Gross margin (TTM)
48.80%
Net profit margin (TTM)
31.94%
Operating margin (TTM)
28.06%
Effective tax rate (TTM)
9.73%
Revenue per employee (TTM)
$930,000
Management effectiveness
Return on assets (TTM)
6.91%
Return on equity (TTM)
15.96%
Valuation
Price to earnings (TTM)
13.026
Price to revenue (TTM)
3.924
Price to book
1.85
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
18.662
Free cash flow yield (TTM)
5.36%
Free cash flow per share (TTM)
2,751.96%
Dividend yield (TTM)
0.34%
Forward dividend yield
0.69%
Growth
Revenue change (TTM)
7.52%
Earnings per share change (TTM)
16.49%
3-year revenue growth (CAGR)
-5.15%
10-year revenue growth (CAGR)
16.48%
3-year earnings per share growth (CAGR)
-17.53%
10-year earnings per share growth (CAGR)
29.26%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Bulls say / Bears say
Regeneron secured a $406 million jury award against Amgen for anticompetitive practices in the cholesterol drug market, potentially enhancing its financial position and market share. (reuters.com)
The company entered a 10-year, $3 billion manufacturing agreement with FUJIFILM Diosynth Biotechnologies to boost U.S. production capacity, supporting future growth. (reuters.com)
Regeneron's anti-inflammatory drug Dupixent, developed with Sanofi, saw a 19% increase in sales to $3.67 billion in Q1 2025, indicating strong demand. (reuters.com)
Regeneron's Q1 2025 earnings missed estimates due to a 26% decline in U.S. sales of its eye disease drug Eylea, attributed to competition and pricing pressures. (reuters.com)
The company faces a securities class action lawsuit alleging false and misleading statements regarding Eylea's Medicare reimbursement compliance, potentially leading to financial and reputational damage. (gurufocus.com)
Analysts have reduced Regeneron's price target due to concerns over Eylea's sales performance and ongoing legal challenges, reflecting a cautious outlook. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
WSJ·9 hours ago
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
GlobeNewsWire·10 hours ago
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
GlobeNewsWire·10 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $54B as of June 20, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 13.03 as of June 20, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $1.76 and the yield is 0.69%. Regeneron has a payout ratio of 2.08% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment date is unconfirmed.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.